Format

Send to

Choose Destination
Expert Opin Biol Ther. 2006 Dec;6(12):1323-31.

Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.

Author information

1
University Hospital of Lausanne (CHUV), Division of Immunology and Allergy, BT06 609, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland. onur.boyman@chuv.ch

Abstract

Initially discovered as a potent T cell proliferation factor, IL-2 was soon used for cancer immunotherapy, especially for metastatic melanoma and renal cell carcinoma; however, the severe side effects of IL-2 therapy, plus the negative role of IL-2 in maintaining of CD4+ CD25+ T regulatory cells (Tregs), has somewhat dampened enthusiasm for using IL-2 in immunotherapy. This opinion article discusses the possibility of combining IL-2 with certain anti-IL-2 antibodies for reducing the dose of IL-2 needed and preferentially stimulating effector T cells, but not Tregs, an approach that might provide an improved strategy for anticancer immunotherapy. Alternatively, complexes of IL-2 with other anti-IL-2 antibodies can selectively stimulate Tregs and could, therefore, be useful for treating autoimmune diseases.

PMID:
17223740
DOI:
10.1517/14712598.6.12.1323
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center